IPO registrations (S-1, F-1) · Registrants
CHIMERIX INC
- SEC CIK
- 1117480 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2013-03-08, last 2013-10-17; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2013-04-11; declared effective 2013-04-10
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 2505 MERIDIAN PARKWAY, SUITE 100, Durham, NC 27713
- EIN
- 33-0903395
- EDGAR entity type
- operating
- Insiders and CEO pay
- CHIMERIX INC on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2013-04-01)
- Final price
- $14.00 per share, within the range (424B4 filed 2013-04-11, an initial public offering)
- Shares sold
- 7,320,000
- Gross proceeds
- $102,480,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CMRX
- Lead underwriters
- Morgan Stanley (3,294,000 shares); Cowen (2,196,000 shares)
- Syndicate
- William Blair (1,098,000); Lazard (732,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CHIMERIX, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CHIMERIX, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CHIMERIX,INC EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: CHIMERIX, INC. EXACT (EIN (EXACT))
- Federal award recipient: CHIMERIX, INC. Fuzzy (name and state)
- Form D issuer: CHIMERIX INC EXACT (CIK (EXACT))
- Lobbying client: CHIMERIX, INC. Fuzzy (name and state)
- Lobbying client: CHIMERIX, INC. Fuzzy (name and state)
- Lobbying client: CHIMERIX, INC. Fuzzy (name and state)
- Lobbying client: CHIMERIX, INC. Fuzzy (name and state)
- SEC filer: CHIMERIX INC EXACT (CIK (EXACT))
- Person page: Michael A Sherman Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
- Person page: Wende S Hutton Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,TenPercentOwner))
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-03-08 | S-1 | S-1 (registration) | CHIMERIX INC | 0001144204-13-014056 ↗ |
| 2013-03-27 | S-1/A | S-1/A (amendment) | CHIMERIX INC | 0001144204-13-017647 ↗ |
| 2013-04-01 | S-1/A | S-1/A (amendment) | CHIMERIX INC | 0001144204-13-018850 ↗ |
| 2013-04-10 | S-1MEF | S-1MEF (added securities) | CHIMERIX INC | 0001144204-13-021187 ↗ |
| 2013-04-10 | EFFECT | EFFECT (declared effective) | CHIMERIX INC | 9999999995-13-000950 ↗ |
| 2013-04-11 | 424B4 | 424B4 (final prospectus) | CHIMERIX INC | 0001144204-13-021201 ↗ |
| 2013-10-08 | S-1 | S-1 (registration) | CHIMERIX INC | 0001144204-13-054339 ↗ |
| 2013-10-17 | S-1/A | S-1/A (amendment) | CHIMERIX INC | 0001144204-13-055496 ↗ |
| 2013-10-18 | 424B4 | 424B4 (final prospectus) | CHIMERIX INC | 0001144204-13-055804 ↗ |
| 2013-10-18 | EFFECT | EFFECT (declared effective) | CHIMERIX INC | 9999999995-13-003021 ↗ |
| 2014-05-16 | EFFECT | EFFECT (declared effective) | CHIMERIX INC | 9999999995-14-001515 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-04-01 | S-1/A | registration statement | $13.00–$15.00 | 6,100,000 | - | Nasdaq CMRX | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2013-04-11 | 424B4 | final prospectus | $14.00 | 7,320,000 | $102,480,000 | Nasdaq CMRX | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG | Other; TenPercentOwner | 2 | 2013 | ||
| ALTA BIOPHARMA PARTNERS III LP | Other; TenPercentOwner | 2 | 2013 | ||
| ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC | Other; TenPercentOwner | 2 | 2013 | ||
| A.M. Pappas Life Science Ventures III, L.P. | Other; TenPercentOwner | 2 | 2013 | ||
| A.M. Pappas Life Science Ventures IV LP | Other; TenPercentOwner | 2 | 2013 | ||
| Berrey M Michelle | Director,Officer; Officer | Chief Medical Officer; Pres, CEO & Chief Medical Ofcr; President and CEO; See Remarks | 29 | 2013–2019 | |
| Canaan Partners VII LLC | Director; Director,TenPercentOwner; TenPercentOwner | 6 | 2013–2014 | ||
| Canaan VII L P | Director; Director,TenPercentOwner; TenPercentOwner | 6 | 2013–2014 | ||
| CHAMPSI FARAH | Director; Director,TenPercentOwner | 3 | 2013 | ||
| DEMSKI MARTHA J | Director | 34 | 2013–2025 | ||
| Hutton Wende S | Director,TenPercentOwner | 4 | 2013 | person page Fuzzy | |
| MARIO ERNEST | Director | 40 | 2013–2018 | ||
| MOCH KENNETH I | Director,Officer | President and CEO | 7 | 2013–2014 | |
| New Leaf Ventures II, L.P. | TenPercentOwner | 5 | 2013–2014 | ||
| NIEDEL JAMES | Director; Director,TenPercentOwner | 9 | 2013–2017 | ||
| PAPPAS ARTHUR M | Director; Director,TenPercentOwner | 3 | 2013 | ||
| PV III CEO Fund, L.P. | Other; TenPercentOwner | 2 | 2013 | ||
| PV IV CEO Fund, L.P. | Other; TenPercentOwner | 2 | 2013 | ||
| Rogers Michael D. | Officer | Chief Development Officer | 6 | 2013–2016 | |
| SANDERLING V BETEILIGUNGS GMBH & CO KG | TenPercentOwner | 4 | 2013 | ||
| SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP | TenPercentOwner | 4 | 2013 | ||
| SANDERLING V BIOMEDICAL LP | TenPercentOwner | 4 | 2013 | ||
| Sanderling Venture Partners V Co Investment Fund, LP | TenPercentOwner | 4 | 2013 | ||
| Sanderling Venture Partners VI Co Investment Fund LP | TenPercentOwner | 5 | 2013–2014 | ||
| Sanderling Venture Partners V, LP | TenPercentOwner | 10 | 2013–2014 | ||
| SANDERLING VENTURES MANAGEMENT V | TenPercentOwner | 4 | 2013 | ||
| Sanderling Ventures Management VI | TenPercentOwner | 4 | 2013 | ||
| Sanderling VI Beteiligungs GmbH & Co KG | TenPercentOwner | 4 | 2013 | ||
| Sanderling VI Limited Partnership | TenPercentOwner | 4 | 2013 | ||
| SANDERLING V LTD PARTNERSHIP | TenPercentOwner | 4 | 2013 | ||
| Sanderling V Strategic Exit Fund LP | TenPercentOwner | 4 | 2013 | ||
| Trost Timothy W. | Officer | See Remarks; Sr. Vice President and CFO; Sr. VP and CFO; Sr. VP & CFO; SVP and CFO; SVP, CFO & Secretary | 31 | 2013–2019 | |
| WOLLAEGER TIMOTHY | Director; Director,TenPercentOwner | 10 | 2013–2016 | ||
| DRAKE RODMAN L | Director | 7 | 2013–2014 | ||
| Richardson Linda M | Officer | Chief Commercial Officer; Chief Commerical Officer | 11 | 2014–2018 | |
| Chambon Philippe O. | TenPercentOwner | 2 | 2014 | ||
| Delagardelle Jeani | TenPercentOwner | 2 | 2014 | ||
| HUNT RONALD | TenPercentOwner | 2 | 2014 | ||
| Lathi Vijay K | TenPercentOwner | 2 | 2014 | ||
| New Leaf Venture Associates II, L.P. | TenPercentOwner | 2 | 2014 | ||
| New Leaf Venture Management II, L.L.C. | TenPercentOwner | 2 | 2014 | ||
| Ratcliffe Liam | TenPercentOwner | 2 | 2014 | ||
| Ricciardi Lisa | Director | 6 | 2014–2016 | ||
| Daly James M | Director | 7 | 2014–2019 | ||
| Gilliss Catherine | Director | 11 | 2014–2023 | ||
| Machado Clarence Patrick | Director | 12 | 2014–2023 | ||
| LEONARD JOHN M. | Director | 8 | 2014–2017 | ||
| Nichols Garrett | Officer | Chief Medical Officer | 20 | 2014–2020 | |
| Renaud Ronald C JR | Director | 7 | 2014–2019 | ||
| Greissing Ed | Director | 5 | 2018–2020 | ||
| Meyer Robert J. | Director | 15 | 2018–2025 | ||
| MIDDLETON FRED A | Director | 21 | 2018–2025 | ||
| Alrutz Michael Albert | Officer | Principal Executive Officer; SVP AND GENERAL COUNSEL | 8 | 2019–2025 | |
| Andriole Michael T. | Director,Officer; Officer | Chief Business Officer; Chief Business Officer and CFO; President and CEO; PRESIDENT AND CEO | 20 | 2019–2025 | |
| Sherman Michael A. | Director,Officer | Chief Executive Officer | 13 | 2019–2025 | person page Fuzzy |
| Jakeman David | Officer | Principal Accounting Officer; VP of Finance and Accounting; VP OF FINANCE AND ACCOUNTING | 24 | 2019–2025 | |
| CANTEX PHARMACEUTICALS, INC. | TenPercentOwner | 3 | 2019–2021 | ||
| Multani Pratik S | Director | 8 | 2020–2025 | ||
| Melemed Allen S. | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 9 | 2020–2025 | |
| Vakiener Victoria | Director | 7 | 2021–2025 | ||
| Riga Thomas J | Officer | COO and CCO | 4 | 2023–2025 | |
| LaSpaluto Michelle | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 8 | 2023–2025 | |
| Decker Lisa Lynn | Director | 4 | 2024–2025 | ||
| KOZIN MARC D | Director | 4 | 2024–2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-07-31 | CHIMERIX INC | Pharmaceuticals | $34,900,000 | $34,900,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CHIMERIX, INC. | NC | State business registries | name and state |
| Plan sponsor | CHIMERIX, INC. | NC | Form 5500 (employee benefit plans) | name and state |
| Federal award recipient | CHIMERIX, INC. | NC | Federal spending (USAspending) | name and state |
| Form D issuer | CHIMERIX INC | NC | Form D private offerings | CIK (EXACT) |
| Lobbying client | CHIMERIX, INC. | NC | Federal lobbying (LDA) | name and state |
| Lobbying client | CHIMERIX, INC. | NC | Federal lobbying (LDA) | name and state |
| Lobbying client | CHIMERIX, INC. | NC | Federal lobbying (LDA) | name and state |
| Lobbying client | CHIMERIX, INC. | NC | Federal lobbying (LDA) | name and state |
| Patent assignee | CHIMERIX, INC. | NC | Patents (USPTO) | name and state |
| SEC filer | CHIMERIX INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Chimerix, Inc. | NC | Trademarks (USPTO) | name and state |
| Business registration | CHIMERIX, INC. | State business registries | EIN (EXACT, as the state registration reports it) | |
| Business registration | CHIMERIX,INC | State business registries | EIN (EXACT, as the state registration reports it) | |
| Form 5500 plan sponsor | CHIMERIX, INC. | EIN (EXACT) | ||
| Person page | Michael A Sherman | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) | |
| Person page | Wende S Hutton | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NC first:
- SALIX PHARMACEUTICALS LTD NC
- TRIANGLE PHARMACEUTICALS INC NC
- INSPIRE PHARMACEUTICALS INC NC
- POZEN INC /NC NC
- ARGOS THERAPEUTICS INC NC
- ENDEAVOR PHARMACEUTICALS INC NC
- CORNERSTONE THERAPEUTICS INC NC
- Talecris Biotherapeutics Holdings Corp. NC
- Biolex Therapeutics, Inc. NC
- CURAXIS PHARMACEUTICAL Corp NC
In other datasets, the same topic (Health) in NC:
- Nonprofit: 24 FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health